Navigation Links
Promising Data on Cognitive Effects of Safinamide in Early,Parkinson's Disease

• Data presented at Movement Disorder Society’s 11th International Congress
• Management of cognitive impairment in early Parkinson’s disease patients is a critical unmet medical need

Geneva, Switzerland, June 8, 2007 – Merck Serono S.A. (virt-x: SEO) and its partner Newron Pharmaceuticals S.p.a. (SWX: NWRN) announced today data, which suggest that safinamide, a new agent in Phase III development for the treatment of Parkinson’s disease, has an effect on cognitive performance in study patients with early Parkinson’s disease. These data were presented yesterday in a poster session at the Movement Disorder Society’s 11th International Congress in Istanbul, Turkey.

The data are from a 6-month (24 weeks), randomized, double blind, placebo-controlled, international Phase III trial. Some results from this trial were presented last month at the American Academy of Neurology 59th Annual Meeting and showed that safinamide significantly improved motor symptoms and activities of daily living for patients in the trial, as an add-on treatment to dopamine agonist therapy1. The cognition testing was carried out in an exploratory manner in selected centers, which agreed to conduct this part of the trial.

“Parkinson’s disease affects several cognitive functions even at an early stage of the disease”, said Professor Anthony Schapira, chairman of the University Department of Clinical Neuroscience, Royal Free and University College London Medical School, and an investigator of the study. "These study results suggest that safinamide may have an effect on cognitive performance in patients with early Parkinson’s disease, and has the potential to address a critical unmet medical need”.

The data demonstrated that the addition of safinamide to a stable dose of a single dopamine agonist in study patients with early stage Parkinson’s disease resulted in
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
7. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
8. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
9. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
10. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
11. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
Post Your Comments:
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... , Sept. 1, 2015 Konica Minolta ... Computed Radiography (CR) system, designed to deliver enterprise level ... utilizing the same Control Station as the Konica Minolta ... with an upgrade path from CR to DR. The ... to help improve workflow with unparalleled reliability and high ...
(Date:9/1/2015)... VEGAS , Sept. 1, 2015  Dr. ... DigiPath Labs , the cannabis testing subsidiary of DigiPath, ... Patients Group about the lack of consistency in ... the online resource for medical cannabis information, she explained ... patients because their lack of uniform requirements makes standardization ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3Konica Minolta Launches New CR System with Low-Cost Upgrade Path to DR 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3
... the ADA,s Annual Scientific Sessions, SAN FRANCISCO, ... of the dose-finding study for its new,injectable diabetes ... American Diabetes Association,s (ADA) 68th Annual Scientific Sessions,meeting ... that AVE0010 was well tolerated and significantly,improved glycemic ...
... California, June 6 , - "ADVANCE Results ... the world,s largest ever study of diabetes treatments,show ... release,gliclazide and other drugs as required, protects patients ... treatment reduces,the risk of kidney disease by one-fifth. ...
Cached Medicine Technology:New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 2New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 3New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 4The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications 2
(Date:9/1/2015)... ... 01, 2015 , ... Zecurion, a leading developer of data loss prevention solutions, ... endpoint DLP developed specifically for Mac OS. , In June 2015, the company successfully ... information security professionals had participated. The beta test done by the developer community enabled ...
(Date:9/1/2015)... ... 01, 2015 , ... The FSH Society , the Massachusetts-based charity that ... will be the beneficiary of a collection of fundraising events this fall. From Boston ... the FSH Society and further FSHD research. , The list of 2015 ...
(Date:9/1/2015)... ... ... Agriculture innovation, urban farming, local food access, and sourcing from sustainable and ... 4th Annual Sustainable Agriculture Conference : “Innovation and the Rise of Local Food,” ... keynotes Pierre Sleiman, founder and CEO of Go Green Agriculture, and Daron “Farmer D” ...
(Date:9/1/2015)... ... September 01, 2015 , ... METTLER TOLEDO ... in accordance with GMP requirements“ , featuring Ed Szczesny (Quality Assurance, Rhodes Pharmaceuticals) ... 11:00 EDT (15:00 GMT). , Calibration, qualification, and the appropriate level of ...
(Date:9/1/2015)... ... 01, 2015 , ... Suzanne Bakken, PhD, RN, FAAN, FACMI ... of Medicine (IOM) of the National Academies. , She is the Alumni Professor ... A member of the Institute of Medicine since 2006, Bakken also currently co-directs ...
Breaking Medicine News(10 mins):Health News:Zecurion Announces Endpoint Security for Mac 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 2Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 4Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 5Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:Columbia Nursing’s Suzanne Bakken Named Distinguished Institute of Medicine Nurse Scholar-in-Residence 2
... for foreign markets and plans,Canadian rollout, ... (OTC,Bulletin Board: UKMA), a lifestyle multimedia and ... personal development, announced today that,its exclusive international ... Xflowsion DVD series at the Electronic,Retailer,s Association ...
... Determinations, WASHINGTON, Oct. 28 National ... Administration,s,new "Compassionate Allowances Process" for disability determinations, ... Before announcing this,proposal, Social Security held public ... information from experts. NPAF, in collaboration with ...
... could reduce the cost and time required for cancer ... 28 online issue of the Journal of the ... a multistep process that involves in vitro tests, animal ... Inadequately designed rodent studies have led to missteps and ...
... DURHAM, N.C. -- Popular cholesterol-busting drugs -- statins -- appear ... according to researchers in the Duke Prostate Center and the ... prevent prostate cancer growth or just mask it is not ... statins were less likely to develop advanced forms of prostate ...
... become a billion-dollar substitute for flying business people ... to make sound judgments about speakers being viewed ... in a journal of the Institute for Operations ... in the Field: A Heuristic Processing Model" is ...
... because it may worsen another is a treatment trade-off ... rather take part in, researchers at Yale School of ... Journal of the American Geriatrics Society . , ... least two chronic conditions, and 24 percent have four ...
Cached Medicine News:Health News:uKarma Reports Progress With International Distribution Agreement for Its Xflowsion DVD Series 2Health News:National Patient Advocate Foundation (NPAF) Commends SSA's New 'Compassionate Allowances Process' 2Health News:Cholesterol-lowering drugs may also lower PSA, but whether they cut cancer risk is still not known 2Health News:Videoconferencing more confusing for decision-makers than face-to-face meetings 2Health News:Elderly fare better when included in decisions on treatment trade-offs 2
... ergonomic chairs with concave seats ... support • Select options like ... and glides. • BTT/1P chairs ... environments: industry, education, laboratory, clean ...
... with concave seats and standard-sized ... Select options like seats, backrests, ... • BTT/1P chairs are recommended ... education, laboratory, clean room, static ...
... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
Medicine Products: